Evidence map›Paper›PMID 40571894›Full record

ArticleAnnals of surgical oncology2025

Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study.

Huayuan Liang, Chengcai Liang, Jiaguang Zhang, Xiaowen Sun, Kaihua Huang, Huimin Zhang, Guoxin Li, Xiaofeng Chen, Liying Zhao

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huayuan Liang *Cancer Center of Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Chengcai Liang *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jiaguang Zhang *The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaowen SunCancer Center of Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Kaihua HuangDepartment of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Baiyun District, Guangdong, China.
Huimin ZhangDepartment of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Baiyun District, Guangdong, China.
Guoxin LiCancer Center of Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Xiaofeng ChenThe First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Liying ZhaoDepartment of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Baiyun District, Guangdong, China. zlyblue11@163.com.

Funding

China Automobile Industry Innovation and Development Joint Fund 82172814Natural Science Foundation of Beijing Municipality L246012Natural Science Foundation of Guangdong Province 2022A1515010267
6 · The paper itself

Abstract

backgroundThe efficacy and safety of conversion surgery after immunotherapy combined with trastuzumab-based chemotherapy for patients with stage IV human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) remains unclear.

methodsThis retrospective multicenter study included patients with stage IV HER2-positive GC treated between February 2012 and October 2024 across three centers in China. Eligible patients had histologically confirmed HER2-positive GC with unresectable stage IV disease treated with trastuzumab-based chemotherapy and/or immunotherapy. Conversion surgery was performed for patients who achieved substantial tumor shrinkage enabling R0 resection.

resultsAmong 232 patients, 114 received chemotherapy combined with trastuzumab alone, whereas 118 were treated with chemotherapy plus immunotherapy and trastuzumab, 50 of whom subsequently underwent conversion surgery. In the cohort receiving chemotherapy and trastuzumab alone, the median progression-free survival (PFS) was 8.2 months (95 % confidence interval [CI], 6.2-10.2 months), and the median overall survival (OS) was 13.9 months (95 % CI, 10.8-17.1 months). The patients who underwent conversion surgery exhibited significantly longer PFS (37.7 vs 10.8 months; P < 0.001) and OS (50.9 vs 22.0 months; P < 0.001) than the non-surgical patients treated with immunotherapy.

conclusionsPreoperative trastuzumab-based chemotherapy combined with immunotherapy followed by conversion surgery significantly improves survival outcomes for patients with stage IV HER2-positive GC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesGastrectomyImmunotherapyStomach NeoplasmsTrastuzumabAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabConversion SurgeryHER2-Positive Gastric CancerImmunotherapyStage IVTrastuzumab-Based Chemotherapy

Identifiers

PMID40571894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.